Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

  • Filters activated: Toxicology. Clear all to show 54 items.
1.

Lipoprotein lipase as a candidate target for cancer prevention/therapy.

Takasu S, Mutoh M, Takahashi M, Nakagama H.

Biochem Res Int. 2012;2012:398697. doi: 10.1155/2012/398697. Epub 2011 Oct 19.

2.

Ibrolipim attenuates high glucose-induced endothelial dysfunction in cultured human umbilical vein endothelial cells via PI3K/Akt pathway.

Xiao G, Wang Z, Zeng H, Yu J, Yin W, Zhang S, Wang Y, Zhang Y.

Pharmazie. 2011 Oct;66(10):798-803.

PMID:
22026163
3.

Pioglitazone-induced body weight gain is prevented by combined administration with the lipoprotein lipase activator NO-1886.

Kusunoki M, Tsutsumi K, Sato D, Nakamura A, Habu S, Mori Y, Morishita M, Yonemoto T, Miyata T, Nakaya Y, Nakamura T.

Eur J Pharmacol. 2011 Oct 15;668(3):486-91. doi: 10.1016/j.ejphar.2011.07.030. Epub 2011 Aug 4.

PMID:
21835171
4.

Preventive effect of Ibrolipim on suppressing lipid accumulation and increasing lipoprotein lipase in the kidneys of diet-induced diabetic minipigs.

Liu Y, Wang ZB, Yin WD, Li QK, Cai MB, Yu J, Li HG, Zhang C, Zu XH.

Lipids Health Dis. 2011 Jul 16;10:117. doi: 10.1186/1476-511X-10-117.

6.

NO-1886 up-regulates Niemann-Pick C1 protein (NPC1) expression through liver X receptor alpha signaling pathway in THP-1 macrophage-derived foam cells.

Ma X, Hu YW, Mo ZC, Li XX, Liu XH, Xiao J, Yin WD, Liao DF, Tang CK.

Cardiovasc Drugs Ther. 2009 Jun;23(3):199-206. doi: 10.1007/s10557-009-6165-8.

PMID:
19229602
7.

Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis.

Yu J, Chu ES, Hui AY, Cheung KF, Chan HL, Leung WK, Farrell GC, Sung JJ.

Biochem Biophys Res Commun. 2007 Apr 27;356(1):53-9. Epub 2007 Mar 5.

PMID:
17350593
8.

NO-1886, a lipoprotein lipase activator, attenuates vascular smooth muscle contraction in rat aorta.

Nakamura A, Harada N, Takahashi A, Mawatari K, Nakano M, Tsutsumi K, Nakaya Y.

Eur J Pharmacol. 2007 Jan 12;554(2-3):183-90. Epub 2006 Oct 10.

PMID:
17109854
9.

NO-1886 upregulates ATP binding cassette transporter A1 and inhibits diet-induced atherosclerosis in Chinese Bama minipigs.

Zhang C, Yin W, Liao D, Huang L, Tang C, Tsutsumi K, Wang Z, Liu Y, Li Q, Hou H, Cai M, Xiao J.

J Lipid Res. 2006 Sep;47(9):2055-63. Epub 2006 Jun 28.

10.
11.

Assessment of induction of cytochrome P450 by NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, in primary cultures of human hepatocytes and in female rat liver.

Morioka Y, Nishimura M, Imai T, Suzuki S, Harada M, Satoh T, Naito S.

Drug Metab Pharmacokinet. 2006 Feb;21(1):19-28.

13.

NO-1886 (ibrolipim), a lipoprotein lipase activator, increases the expression of uncoupling protein 3 in skeletal muscle and suppresses fat accumulation in high-fat diet-induced obesity in rats.

Kusunoki M, Tsutsumi K, Iwata K, Yin W, Nakamura T, Ogawa H, Nomura T, Mizutani K, Futenma A, Utsumi K, Miyata T.

Metabolism. 2005 Dec;54(12):1587-92.

PMID:
16311090
14.

Lipoprotein lipase activator NO-1886 improves fatty liver caused by high-fat feeding in streptozotocin-induced diabetic rats.

Kusunoki M, Tsutsumi K, Inoue Y, Hara T, Miyata T, Nakamura T, Ogawa H, Sakakibara F, Fukuzawa Y, Okabayashi N, Kato K, Ikeda H, Kurokawa T, Ishikawa T, Otake K, Nakaya Y.

Metabolism. 2004 Feb;53(2):260-3.

PMID:
14767881
15.

Pharmacokinetics and metabolism of NO-1886, a lipoprotein lipase-promoting agent, in cynomolgus monkey.

Morioka Y, Harada M, Imai T, Naito S.

Xenobiotica. 2003 Dec;33(12):1247-60.

PMID:
14742146
16.
17.

Effect of the lipoprotein lipase activator NO-1886 on adriamycin-induced nephrotic syndrome in rats.

Nakayama K, Hara T, Kusunoki M, Tsutsumi K, Minami A, Okada K, Sakamoto S, Ohnaka M, Miyata T, Nakamura T, Aoki T, Fukatsu A, Nakaya Y, Kakumu S.

Metabolism. 2000 May;49(5):588-93.

PMID:
10831167
18.

NO 1886.

[No authors listed]

Drugs R D. 1999 Jun;1(6):488-9. No abstract available.

PMID:
10566092
19.

Metabolism of diethyl 4-[(4-bromo-2-cyanophenyl)-carbamoyl]benzylphosphonate in the rat.

Morioka Y, Ohmizo M, Harada M, Goto K, Naito S, Tsutsumi K.

Xenobiotica. 1996 Aug;26(8):853-61.

PMID:
8879149
20.

Synthesis and hypolipidemic activities of novel 2-[4-[diethoxyphosphoryl)methyl]phenyl]quinazolines and 4(3H)-quinazolinones.

Kurogi Y, Inoue Y, Tsutsumi K, Nakamura S, Nagao K, Yoshitsugu H, Tsuda Y.

J Med Chem. 1996 Mar 29;39(7):1433-7.

PMID:
8691473

Supplemental Content

Loading ...
Support Center